Use of Traditional and Biventricular Implantable Cardiac Devices for Primary and Secondary Prevention of Sudden Death

Cardiology Clinics

Volumn 26, Issue 3, 2008, Pages 419-431

  Klein, Matthew H ^a   Gold, Michael R ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; PROPAFENONE; SOTALOL;

ARTIFICIAL HEART PACEMAKER; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY BYPASS SURGERY; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; DRUG EFFICACY; DRUG SAFETY; EXERCISE; FOLLOW UP; HEART ARRHYTHMIA; HEART ATRIUM PACING; HEART DEATH; HEART EJECTION FRACTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE EJECTION TIME; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE PACING; HEART VENTRICLE TACHYCARDIA; HUMAN; LIFE EXPECTANCY; MORTALITY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; QRS COMPLEX; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; RISK FACTOR; SECONDARY PREVENTION; ST SEGMENT ELEVATION; SUDDEN DEATH; SURVIVAL RATE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CARDIAC PACING, ARTIFICIAL; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HUMANS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FIBRILLATION;

EID: 44449103130     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2008.03.006     Document Type: Review

References (71)

1. Zheng Z.J., Croft J.B., Giles W.H., et al. Sudden cardiac death in the United States, 1989 to 1998. Circulation 104 18 (2001) 2158-2163
2. Bigger J.T. Expanding indications for implantable cardiac defibrillators. N Engl J Med 346 12 (2002) 931-933
3. de Vreede-Swagemakers J.J., Gorgels A.P., Dubois-Arbouw W.I., et al. Out-of-hospital cardiac arrest in the 1990s: a population-based study in the Maastricht area on incidence, characteristics, and survival. J Am Coll Cardiol 30 6 (1997) 1500-1505
4. Weaver W.D., Hill D., Fahrenbruch C.E., et al. Use of the automatic external defibrillator in the management of out-of-hospital cardiac arrest. N Engl J Med 319 11 (1988) 661-666
5. Merit-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: the Metoprolol CR/Xl Randomized Intervention Trial In Congestive Heart Failure (MERIT-HF). Lancet 353 9169 (1999) 2001-2007
6. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmic Versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 337 22 (1997) 1576-1583
7. Connolly S.J., Gent M., Roberts R.S., et al. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 101 11 (2000) 1297-1302
8. Kuck K.H., Cappato R., Siebels J., et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 102 7 (2000) 748-754
9. Nademanee K., Veerakul G., Mower M., et al. Defibrillator versus beta-blockers for unexplained death in Thailand (DEBUT): a randomized clinical trial. Circulation 107 17 (2003) 2221-2226
10. Lau E.W., Griffith M.J., Pathmanathan R.K., et al. The Midlands Trial Of Empirical Amiodarone Versus Electrophysiology-guided Interventions and Implantable Cardioverter-Defibrillators (MAVERIC): a multicentre prospective randomized clinical trial on the secondary prevention of sudden cardiac death. Europace 6 4 (2004) 257-266
11. Naccarelli G.V., Wolbrette D.L., Dell'Orfano J.T., et al. A decade of clinical trial developments in postmyocardial infarction, congestive heart failure, and sustained ventricular tachyarrhythmia patients: from CAST to AVID and beyond. J Cardiovasc Electrophysiol 9 8 (1998) 864-891
12. Buxton A.E., Lee K.L., Hafley G.E., et al. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol 50 12 (2007) 1150-1157
13. Larsen G., Hallstrom A., McAnulty J., et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy. Circulation 105 17 (2002) 2049-2057
14. Connolly S.J., Hallstrom A.P., Cappato R., et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials: AVID, CASH, and CIDS studies. Eur Heart J 21 24 (2000) 2071-2078
15. Lee D., Green L., Liu P., et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol 41 9 (2003) 1573-1582
16. Domanski M.J., Sakseena S., Epstein A.E., et al. Relative effectiveness of the implantable cardioverter defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators. J Am Coll Cardiol 34 4 (1999) 1090-1095
17. Sheldon R., Connolly S., Krahn A., et al. Identification of patients most likely to benefit from implantable cardioverter defibrillator therapy. The Canadian Implantable Defibrillator Study. Circulation 101 14 (2000) 1660-1664
18. Domanski M.J., Epstein A., Hallstrom A., et al. Survival of antiarrhythmic or implantable cardioverter defibrillator-treated patients with varying degrees of left ventricular dysfunction who survived malignant ventricular arrhythmias. J Cardiovasc Electrophysiol 13 6 (2002) 580-583
19. Exner D.V., Sheldon R.S., Pinski S.L., et al. Do baseline characteristics accurately discriminate between patients likely versus unlikely to benefit from implantable defibrillator therapy? Evaluation of the Canadian implantable defibrillator study implantable cardioverter defibrillator efficacy score in the antiarrhythmics versus implantable defibrillators trial. Am Heart J 141 1 (2001) 99-104
20. Hallstrom A.P., McAnulty J.H., Wilkoff B.L., et al. Patients at lower risk of arrhythmia recurrence: a subgroup in whom implantable defibrillators may not offer benefit. Antiarrhythmics Versus Implantable Defibrillator (AVID) trial investigators. J Am Coll Cardiol 37 4 (2001) 1093-1099
21. Raitt M., Klein R., Wyse G., et al. Comparison of arrhythmia recurrence in patients presenting with ventricular fibrillation versus ventricular tachycardia in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. Am J Cardiol 91 7 (2003) 812-816
22. Wyse D.G., Friedman P.L., Brodsky M.A., et al. Life-threatening ventricular arrhythmias due to transient or correctable causes: high risk for death in follow-up. J Am Coll Cardiol 38 6 (2001) 1718-1724
23. Anderson J.L., Hallstrom A.P., Cappato R., et al. Design and results of the Antiarrhythmics vs Implantable Defibrillators (AVID) registry. AVID investigators. Circulation 99 13 (1999) 1692-1699
24. Raitt M.H., Renfroe E.G., Epstein A.E., et al. Stable ventricular tachycardia is not a benign rhythm: insights from the Antiarrhythmics Versus Implantable Defibrillators (AVID) registry. Circulation 103 2 (2001) 244-252
25. Exner D.V., Reiffel J.A., Epstein A.E., et al. Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 34 2 (1999) 325-333
26. Schron E.B., Exner D.V., Yao Q., et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 105 5 (2002) 589-594
27. Irvine J., Dorian P., Baker B., et al. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J 144 2 (2002) 282-289
28. Brodsky M.A., Mitchell L.B., Halperin B.D., et al. Prognostic value of baseline electrophysiologic studies in patients with sustained ventricular tachyarrhythmia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. Am Heart J 144 3 (2002) 478-484
29. Exner D.V., Pinski S.L., Wyse D.G., et al. Electrical storm presages nonsudden death: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. Circulation 103 16 (2001) 2066-2071
30. Bokhari F., Newman D., Greene M., et al. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Circulation 110 2 (2004) 112-116
31. Prystowsky E.N. Prevention of sudden cardiac death. Clin Cardiol 28 11 Suppl 1 (2005) I12-I18
32. Moss A.J., Hall W.J., Cannom D.S., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 335 26 (1996) 1933-1940
33. Mushlin A.I., Hall W.J., Zwanziger J., et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation 97 21 (1998) 2129-2135
34. Buxton A.E., Lee K.L., Fisher J.D., et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 341 25 (1999) 1882-1890 [Erratum, N Engl J Med 2000;342(17): 1300]
35. DiMarco J.P. Implantable cardioverter defibrillators. N Engl J Med 349 19 (2003) 1836-1847
36. Buxton A.E., Lee K.L., Dicarlo L., et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. N Engl J Med 342 26 (2000) 1937-1945
37. Goldberger Z., and Lampert R. Implantable cardioverter defibrillators: expanding indications and technologies. JAMA 295 7 (2006) 809-818
38. Buxton A.E., Lee K.L., Hafley G.E., et al. Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease. An analysis of patients enrolled in the multicenter unsustained tachycardia trial. Circulation 106 19 (2002) 2466-2472
39. Russo A.M., Hafley G.E., Lee K.L., et al. Racial differences in outcome in the multicenter unsustained tachycardia trial (MUSTT): a comparison of whites versus blacks. Circulation 108 1 (2003) 67-72
40. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 12 (2002) 877-883
41. Wilber D.J., Zareba W., Hall W.J., et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 109 9 (2004) 1082-1084
42. Goldenberg I., Moss A.J., McNitt S., et al. Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 47 9 (2006) 1811-1817
43. Zareba W., Piotrowicz K., McNitt S., et al. Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population). Am J Cardiol 95 12 (2005) 1487-1491
44. Goldenberg I., Moss A.J., McNitt S., et al. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol 98 4 (2006) 485-490
45. Pietrasik G., Goldenberg I., McNitt S., et al. Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients. J Cardiovasc Electrophysiol 18 2 (2007) 181-184
46. Moss A.J., Greenberg H., Case R.B., et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 110 25 (2004) 3760-3765
47. Singh J.P., Hall W.J., McNitt S., et al. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation. J Am Coll Cardiol 46 9 (2005) 1712-1720
48. Vorobiof G., Goldenberg I., Moss A.J., et al. Effectiveness of the implantable cardioverter defibrillator in blacks versus whites (from MADIT-II). Am J Cardiol 98 10 (2006) 1383-1386
49. Zareba W., Moss A.J., Jackson Hall W., et al. Clinical course of implantable cardioverter defibrillator therapy in postinfarction women with severe left ventricular dysfunction. J Cardiovasc Electrophysiol 16 12 (2005) 1265-1270
50. Zwanziger J., Hall W.J., Dick A.W., et al. The cost-effectiveness of implantable defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 47 11 (2006) 2310-2318
51. Strickberger S.A., Hummel J.D., Bartlett T.G., et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol 41 10 (2003) 1707-1712
52. Bänsch D., Antz M., Boczor S., et al. Primary prevention of sudden death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 105 12 (2002) 1453-1458
53. Kadish A., Schaechter A., Subacius H., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 21 (2004) 2151-2158
54. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 3 (2005) 225-237
55. Mark D.B., Nelson C.L., Anstrom K.J., et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 114 2 (2006) 135-142
56. Singh S.N., Poole J., Anderson J., et al. Role of amiodarone or implantable cardioverter defibrillator in patients with atrial fibrillation and heart failure. Am Heart J 152 5 (2006) 974 e7-11
57. Nanthakumar K., Epstein A.E., Kay G.N., et al. Prophylactic implantable cardioverter defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 44 11 (2004) 2166-2172
58. Bigger Jr. J.T. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 337 22 (1997) 1569-1575
59. Veenhuyzen G.D., Singh S.N., McAreavey D., et al. Prior coronary artery bypass surgery and risk of death among patients with ischemic left ventricular dysfunction. Circulation 104 13 (2001) 1489-1493
60. Hohnloser S.H., Kuck K.H., Dorian P., et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351 24 (2004) 2481-2488
61. Nolan J., Batin P.D., Andrews R., et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 98 15 (1998) 1510-1516
62. Healey J.S., Toff W.D., Lamas G.A., et al. Cardiovascular outcomes with atrial-based pacing compared with ventricular pacing: meta-analysis of randomized trials, using individual pacing data. Circulation 114 1 (2006) 3-5
63. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 350 21 (2004) 2140-2150
64. Cleland J.G., Daubert J.C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 15 (2005) 1539-1549
65. Freemantle N., Tharmanathan P., Calvert M.J., et al. Cardiac resynchronisation for patients with heart failure due to left ventricular systolic dysfunction-a systematic review and meta-analysis. Eur J Heart Fail 8 4 (2006) 433-440
66. Higgins S.L., Hummel J.D., Niazi I.K., et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 42 8 (2003) 1454-1459
67. Young J.B., Abraham W.T., Smith A.L., et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced heart failure. The MIRACLE ICD trial. JAMA 289 20 (2003) 2685-2694
68. Cazeau S., Leclercq C., Lavergne T., et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 344 12 (2001) 873-880
69. Leclercq C., Walker S., Linde C., et al. Comparative effects of permanent biventricular and right univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 23 22 (2002) 1780-1787
70. Leclercq C., Cazeau S., Lellouche D., et al. Upgrading from right ventricular pacing to biventricular pacing in previously paced patients with advanced heart failure: a randomized controlled study. Pacing Clin Electrophysiol 30 Suppl 1) (2007) S23-S30
71. Abraham W.T., Fisher W.G., Smith A.L., et al. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 346 24 (2002) 1845-1853